WVE 006
Alternative Names: AIMers; GSK-5462688; SERPINA1 stereopure nucleic acid therapeutic - WaVe Life Sciences; WVE-006Latest Information Update: 05 Feb 2026
At a glance
- Originator WaVe life Sciences
- Class Amides; Amino sugars; Drug conjugates; Oligonucleotides
- Mechanism of Action Gene expression modulators
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Alpha 1-antitrypsin deficiency
Most Recent Events
- 02 Feb 2026 WVE 006 is no longer licensed to GSK in Workd
- 02 Feb 2026 Wave Life Sciences plans to advance the registrational strategy for WVE 006, with US FDA feedback on a potential accelerated approval pathway expected by mid 2026
- 06 Nov 2025 Efficacy data from phase Ib/IIa RestorAATion-2 trial in Alpha-1 antitrypsin deficiency released by Wave Life Sciences